Part 10: Regeneration, Stem Cells & Paralysis

“If it worked in rats, it will work in humans”

Animal models have driven spinal cord injury and disc degeneration research for decades, and some of the most promising early-stage results — complete neurological recovery in rodents after various interventions — created enormous public excitement. The translation gap is real and persistent.

Why animal results frequently do not replicate in humans:

• Rodent spinal cords are anatomically and functionally different from human cords
• The timing of injury to intervention in animal studies is often acute; most human patients present sub-acutely or chronically, when the injury environment is completely different
• Animal study sample sizes are typically small, and publication bias means negative results are underrepresented
• Outcome measures in animals (grid walking, swimming, beam walking) do not map directly to human functional outcomes
• A 2019 analysis from Ohio State University found widespread bias in SCI animal studies — including failure to report excluded animals, absence of allocation concealment, and lack of blinded outcome assessment — leading to systematic overestimation of treatment efficacy

This does not mean animal studies are worthless. They are essential for generating hypotheses and understanding mechanisms. But they are the first step of a long journey, not evidence that a treatment works in humans.

“A clinical trial listing means the treatment is proven”

ClinicalTrials.gov is a database that registers clinical research — not a registry of approved or proven treatments. The FDA specifically states that listing on ClinicalTrials.gov does not mean a product is legally marketed, FDA-approved, or proven effective.

The difference between trial phases matters enormously:

• Phase 1: Safety and dosing — a small number of patients, primary goal is to establish whether the treatment causes serious harm
• Phase 2: Efficacy signal — is there evidence it might work? Still too early to recommend broadly
• Phase 3: Definitive efficacy — large, randomised, controlled trial required before approval
• FDA approval: The end point of this process — not the beginning

When a clinic tells you a treatment is "in clinical trials" or "being studied at major centres," that is a description of where the science is — it is not a basis for paying for it outside of those trials.

“FDA registered means FDA approved”

FDA registration describes a facility that has met administrative requirements to operate. FDA approval describes a product that has been reviewed and found safe and effective for a specific indication through a full regulatory process.

These are completely different things. A clinic can be FDA-registered and offer nothing that is FDA-approved. A product can be "FDA listed" — entered into a database — without having been reviewed or approved.

When evaluating any regenerative medicine claim, ask specifically: "Is this product FDA-approved for my indication?" Not "registered," not "listed," not "recognised," not "compliant" — approved.

“My own cells cannot harm me — autologous means safe”

Autologous means derived from your own body. It does not mean safe. Several important risks remain:

• Processing contamination: Between harvest and re-injection, autologous cells are processed, concentrated, and sometimes cultured. Each step introduces contamination risk.
• Wrong tissue behaviour: Adipose-derived cells injected into the disc or spinal fluid may not behave as intended — they enter a completely different microenvironment from where they originated.
• Inflammatory reaction: Reintroducing processed cells into a new anatomical location can trigger local inflammatory responses, particularly in the avascular disc environment.
• Intrathecal injection risks: Injecting any substance into the spinal fluid — including your own cells — carries risks of headache, infection, and potentially serious neurological events if contamination or inflammatory responses occur at this anatomical level.

The FDA specifically notes that autologous products are not exempt from regulation simply because they originate from the patient's own body — if the processing steps are extensive enough to constitute manufacture of a biological product, FDA oversight applies.

“Walking is the only recovery that matters after SCI”

Research consistently shows that people with SCI rank priorities differently from what outside observers assume. When patients with spinal cord injury are asked directly what recovery matters most to them:

• Hand and arm function is the top priority for tetraplegic patients — more so than walking
• Bladder and bowel function is consistently ranked as a top-three priority across injury levels
• Sexual function, reduction of chronic pain, spasticity control, and trunk stability matter enormously for independence and quality of life
• Walking, while deeply symbolic, is ranked lower than clinicians and families often assume

This matters for two reasons. First, it changes how we should evaluate research outcomes — a trial showing improved hand grip in tetraplegics may be more clinically meaningful than one showing limited locomotor recovery. Second, it protects patients from fixating on an outcome that may not be achievable while overlooking gains that would substantially change their daily lives.

The most sophisticated, patient-centred rehabilitation programmes are organised around what the patient actually values — not what looks best in a fundraising video.

Complete vs. Incomplete Spinal Cord Injury — the Distinction That Changes Everything

The American Spinal Injury Association (ASIA) Impairment Scale grades neurological status from A to E:

The distinction between A and B/C/D is profoundly important for prognosis, for eligibility for certain interventions, and for understanding what recovery is possible. Most of the dramatic recovery stories in the media — including many involving stimulation and stem cells — involve incomplete injuries (B, C, or D). Some degree of spontaneous neurological recovery can also occur in incomplete injuries in the first 6–12 months even without specific intervention.

When evaluating any claim about SCI treatment, always ask: what was the ASIA grade of the patients included?